Core data product
Protocol-aligned oncology cohorts for defined evidence questions.
Cohort scope is defined by the indication, eligibility criteria, clinical variables, endpoints, follow-up, and intended use.
Illustrative example — cohort overview
Cohort size
934
Median age
63 yr
Female
50.4%
Median follow-up
16.7 mo
Feasibility funnel
Definition
What the licensed cohort includes.
Protocol aligned
Population and eligibility criteria mapped to the study.
Clinician curated
Medical review applied where clinical context affects interpretation.
Endpoint focused
Longitudinal outcomes selected for the study question.
Traceable
Provenance and quality information delivered with the cohort.
Product workflow
From feasibility to delivery.
- 01
Feasibility
Confirm population, variables, endpoints, and follow-up.
- 02
Cohort build
Apply study criteria, curation, and quality review.
- 03
Delivery
Provide analysis-ready data and supporting documentation.
Data depth
Configure the cohort around the evidence question.
Population
- Indication and stage
- Line of therapy
- Eligibility criteria
Clinical depth
- Treatment and labs
- Biomarkers / genomics
- Baseline characteristics
Endpoints
- Response
- Progression
- Survival and safety
Data quality
Every cohort is delivered with a rich cancer baseline characterization.
Each licensed cohort includes baseline characteristics and quality reporting defined for the engagement.
Advanced solid tumour · 2L+, grouped by category — demographics, disease extent, performance status, prior therapy, biomarkers, and follow-up.
Illustrative example — baseline characteristics
| Age | 63[55–70] yr |
|---|---|
| Sex | |
Female471(50.4%)Male463(49.6%) | |
Illustrative example — data quality
Median follow-up
18.6 mo
Field completeness by data domain, illustrative example.